The NIO Infant™ provides safe, rapid intraosseous access in the proximal tibia as an alternative to IV access in emergency medical situations.
When you need rapid IO access in infant patients, trust the NIO Infant™ to deliver safe, effective vascular access — no batteries, assembly, or extra parts required. Designed for patients from 2.3kg to 3 years of age, the NIO Infant™ features a 5mm marker line on its cannula, which confirms adequate needle length prior to insertion, while its unique Stepped Needle® delivers graduated penetration into the bone, helping to prevent over-penetration. Simple and safe-by-design, you can trust the NIO Infant™ to provide rapid infant IO access when every second counts.
Features:
- Unique Stepped Needle® that delivers graduated penetration into the medullary cavity, helping to prevent over-penetration.
- 5mm marker line which confirms adequate needle length prior to insertion.
- No batteries, assembly or extra parts required.
- Pocket-sized and lightweight
- Sterile and single-use—eliminates the risk of cross-contamination.
- 5-year shelf life (at room temp.)
- Hyper-realistic training system
- Legal Manufacturer: WaisMed Ltd.
- PN: NIO-I
- Needle gauge: 18G Stepped Needle®
- Device dimensions: 4.76in x 1.69in x 1.3in (11.7cm x 4.3cm x 3.3cm)
- Package dimensions: 6.81in x 2.74in x 1.46in (17.3cm x 6.95cm x 3.7cm)
- Weight: 2.5oz (71g)
- Shelf life: 5 years at room temperature
Clinically Proven Success
Safe on the bone.
The NIO has proven to be safe on the bone and resulted in zero incidents of bone fracture as observed by post-insertion x-rays.
Easily tolerates common user errors.
A recent study evaluated common user errors related to needle placement and found that even when placed up to 5cm from the correct insertion site, the NIO maintained an 85% success rate.
First attempt success rates as high as 98%.
Initial studies demonstrated an overall average success rate of 91.3% for the proximal tibia and 93.1% for the humeral head. The New York Institute of Osteopathic Medicine conducted an additional study which established a proximal tibia success rate of over 98%1
